Alfahealth is a company built on Engineering’s long-standing experience in the healthcare sector, from which it inherits expertise, people, and assets. Its dual objective is to continue providing integrated end-to-end solutions throughout the entire citizen/patient journey and to effectively support healthcare professionals in their diagnostic and treatment activities, enriching their experience with innovative tools and technologies to monitor outcomes and generate clinical knowledge.

Its mission is to digitalize and orchestrate clinical and healthcare processes by engaging citizens/patients and professionals, while leveraging data generated through clinical activities to support decision-making, create and share clinical knowledge, measure outcomes, and enable predictive, preventive, personalized, and participatory models of care. Alfahealth is uniquely positioned to support healthcare organizations, institutions, and public bodies through a robust organizational structure of approximately 1,200 specialists, including project and program managers, account, sales and presales managers, designers and developers, organizational consultants, and application consultants, drawing on more than 40 years of experience.

Alfahealth offers a portfolio of solutions that supports all hospital and community healthcare processes. Its expertise spans clinical, administrative, and governance domains, along with the capability to initiate and manage highly complex programs at both regional and national levels, ensuring tangible and measurable continuity of care between hospitals and community-based healthcare services.

On June 17, 2026, it was announced that the Engineering Group had signed two binding agreements with Accenture for the sale of the entire share capital of Alfahealth S.p.A., which operates in the transformation of the Italian healthcare sector, and of the Industries eXcellence Group, which is active in the development and delivery of digital solutions for industrial sectors, with a primary focus on the United States and selected European markets. The transactions are subject to the customary conditions precedent, including, by way of example, Antitrust and Golden Power approvals, and are expected to be completed in the fourth quarter of the current fiscal year.